Coursera Cuts Jobs Despite $100M Revenue Milestone

Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

YouTube

PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics

Ambry Genetics via YouTube

Start learning Write review

Overview

Explore modern examples of ovarian cancer diagnoses and treatments in this informative webinar. Gain a comprehensive overview of ovarian cancer development, risk factors, and therapies, with a special focus on PARP inhibitors and their role in treatment. Dr. Annekathryn Goodman delves into topics such as cancer probability, symptom frequency, classification of ovarian cancer, regulatory pathways, standard of care, and hereditary susceptibility. Learn about targeted therapies, including PARP inhibitors and their mechanism of action, as well as clinical trials and side effect profiles. Discover the latest advancements in ovarian cancer treatment, including angiogenesis targeting and VEGF inhibitors. This 54-minute presentation offers valuable insights for healthcare professionals and those interested in understanding the complexities of ovarian cancer management.

Syllabus

Intro
Disclosures
OUTLINE
GOALS LEARNING OBJECTIVES
Cancer Probability for Females at Birth - USA
Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
EPITHELIAL OVARIAN CANCER SIGNS
OVARIAN CANCER CLASSIFICATION
Epithelial Ovarian Cancer Cont... Five main histologic subtypes
Regulatory Pathways
Mucinous Carcinoma
Standard of Care
Chemotherapy Recurrent Disease Platinum Sensitive
Conventional Chemotherapy Side Effects
Cost Comparison Among Ovarian Cancer Treatments
Hereditary Susceptibility to
Clinical manifestation of hereditary ovarian cancer
LIFETIME RISK ESTIMATED IN BRCA1 & BRCA2 CARRIERS
BRCA1-RELATED OVARIAN CANCER
Hereditary breast and ovarian cancer syndrome (HBOC)
Targeted Therapies
Poly(ADP-Ribose) Polymerase (PARP) inhibition in ovarian cancer
PARP Inhibitors: Mechanism of Action
PARP Family
PARP Inhibitors Background
High Grade Serous Cancers (HGSC) & BRCA mutations
Phase I trial: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
PARP Inhibitors: Properties & Side Effects
Olaparib Clinical Trials
Ovarian cancer trials PARP 1 & 2 Inhibitors
Targeting Angiogenesis: VEGF
VEGF: Tyrosine kinase Inhibitor
Randomized phase II trial: Olaparib with Cediranib vs Olaparib alone in recurrent platinum sensitive
PARP Inhibitor Side effect Profile
In Summary
Targeting Therapies: Summary

Taught by

Ambry Genetics

Reviews

Start your review of PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics

Start learning

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Sign up for free
Someone learning on their laptop while sitting on the floor.